0OIR Six-month Interim Report (Q2) 2022
11 August 2022 - 03:29PM
UK Regulatory
TIDMALK TIDMB
Bemærk venligst, at rapporten udelukkende findes på engelsk.
ALK reports Q2 revenue up 17%, EBITDA up 123%, and full-year
outlook upgraded (unaudited)
Performance in Q2 was better than expected with double-digit
growth in all regions and ALK reported its best-ever Q2 results.
Total revenue was up 17% led by sales growth from tablets and
Jext(R) . In Europe, ALK's largest region, sales were up 14% and
bounced back strongly after the COVID-led headwinds of Q1.
Operating profit (EBITDA) increased 123% on sales growth and
improved gross margin. Based on the strong sales momentum, ALK has
upgraded its financial outlook for 2022.
Q2 2022 financial highlights
-- Total revenue was up 17% in local currencies to DKK 1,045 million (868).
Currencies had a positive effect of 3 percentage points, resulting in
reported growth of 20%. Revenue for the first six months was up 14% in
local currencies (16% reported growth) with tablet sales growth of 21%.
-- Tablet sales grew 18% to DKK 480 million (401) on increasing uptake in
Europe, where sales were up 21%. Global growth was softened by the
phasing of product shipments to Japan.
-- Combined SCIT and SLIT-drops sales grew 4% on the recovery in Europe and
higher revenue from China, while sales of other products grew due to
significantly improved Jext(R) sales.
-- Gross margin improved to 61% (58) primarily on sales growth and
efficiencies.
-- Operating profit (EBITDA) increased 123% in reported currency to DKK 107
million (48), on strong sales growth and improved gross margin, while R&D
and sales and marketing expenses were largely as planned. EBITDA for the
first six months was up 38% at DKK 379 million (274).
Key events and strategic progress
ALK continued to make good progress on its strategic priorities
and remained resilient to other challenges. In Q2:
-- ALK initiated a Phase I clinical trial with its SLIT-tablet for the
treatment of peanut allergy. The trial will assess the tolerability and
safety of dosing with a SLIT-tablet against peanut allergy taken once
daily.
-- ALK's two pivotal, Phase III paediatric trials of its house dust mite and
tree tablets remain on course for completion in 2023.
-- ALK signed an expanded agreement with contract manufacturer Catalent,
which secures long-term manufacturing capacity for the SLIT-tablet
portfolio to accommodate ALK's strategic growth ambitions towards 2030.
2022 financial outlook
As announced on 4 August 2022, based on a strong sales momentum
and the outlook for the remainder of the year, ALK has upgraded its
full-year outlook:
-- Revenue is now expected to grow 10-13% in local currencies (previously:
8-12%).
-- EBITDA is now expected to increase to DKK 675-750 million (previously:
625-725).
Hørsholm, 11 August 2022
ALK-Abelló A/S
Comparative figures for 2021 are shown in brackets. Revenue
growth rates are stated in local currencies, unless otherwise
indicated
For further information, contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile
+45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
Today, ALK is hosting a conference call for analysts and
investors at 1.30 p.m. (CEST) at which Management will review the
financial results and the outlook. The conference call will be
audio cast on
https://www.globenewswire.com/Tracker?data=I9aaydl5l3LME-1H1Umy7nXhBaOGA3DA-X27BDoU76X6pH37pr4hR1aSh8BfReGLuDyYVEe3GyCKp6ycZTWcTg==
https://ir.alk.net where the relevant presentation is available
shortly before the call begins. Please call in before 1.25 p.m.
(CEST). Danish participants should call in on tel. +45 7877 4197
and international participants should call in on tel. +44 808 101
1183 or +1 785 424 1226. Please use the Participant Pin Code:
35630#
Vedhæftet fil
-- FM_14_22UK_11082022
https://ml-eu.globenewswire.com/Resource/Download/4a9711dc-4361-4e94-8182-061c2a3a0121
(END) Dow Jones Newswires
August 11, 2022 01:29 ET (05:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From Mar 2023 to Mar 2024